(0.38 mg/kg body weight) and BT-PABA (10 mg/kg body weight) were administered through a stomach tube. The excretion ratio of BT-PABA in 6 h cumulative urine was calculated.
To study activities of enzymes in the pancreas, serum amylase, lipase, elastase and trypsin activities were measured. To determine hormone activity in blood, levels of immunoreactive insulin (IRI), testosterone and corticosterone were measured. Enzyme activities and hormone levels in blood were measured at Mitsubishi Chemical BCL Corp. using a commercially available kit. Statistical analyses of differences in PFD test result between before and after the treatment. While those in pancreatic enzyme activity and IRI concentration between the treated and non-treated groups were performed using Student's t-test.
2 Pharmacological evaluation 1) Screening of drugs which inhibit development of pancreatitis Drugs were administered to the 8-to 15-weekold rats for 8 weeks, during which the initial stage of pancreatitis was observed. Drugs which were considered to inhibit the development of pancreatitis were screened. The 8 weeks old male WBN rats were categorized into 5 drug-administration groups [ (A), (B) , (C), (D) and (E) (4 rats for each group) ] and the non-treated group (F) (4 rats). The exocrine PFD study, administration of drugs and the histopathological study were carried out according to the following schedule: ( 1 ) The initial PFD test was performed on rats at 8 weeks old before the administration of drugs.
(2) Drugs were administered for 8 weeks. (3) Two days after the completion of drug administration, the PFD test was performed following the method described in (1) . (4) (1) Non-treated (control) group : The pancreatic specimens ( Fig. 2-f ) from all 4 rats at 16 weeks old in the non-treated group exhibited a pancreatitic area larger than 51% (Table 1) . Therefore, when the percentage of pancreatitis was lower than 50% following the administration of a drug in the screening test, we determined the drug to be effective in treating pancreatitis.
(2) Estradiol-treated group: Estradiol was administered intraperitoneally twice a week. Depending on the administered amount, the rats were categorized into a high-estradiol group (40 , body weight) and a low-estradiol group ( 2.6 ng/ml) ( Table 2 ).
(4) SOD-catalase combined-treated group: superoxide dismutase (SOD) (50 mg/kg body weight) and catalase (10 mg/kg body weight) were separately dissolved in 0.5 ml of physio- 2-c, Table 1 ), indicating that no functional or histopathological improvement occurred.
(5) Allopurinol-treated group : Allopurinol (100 mg/kg body weight/day) was perorally administered daily. The PFD level was significantly increased after the administration compared to the before (Table 2 ). Other than the significant increase in the serum amylase level and the significant decrease in the IRI level, no statistically significant differences in the pancreatic enzyme series or hormone levels were observed between the treated and control groups (Table 2) . Histopathologically, a localized inflammatory area was observed in the treated group ; however, the pancreatic parenchyma remained intact ( Fig. 2-d) . Two rats exhibited a lower than 25% pancreatitic area and another 2 rats a 25-50% pancreatitic area (Table  1) . weeks old, representing a condition typical of chronic pancreatitis (Fig. 3-c) . Among 7 rats in the non-treated group, 5 rats exhibited a pancreatitic area larger than 76% and 51-75% in 2 rats (Table 4) , these rats showed very severe and severe lesions, respectively. In addition, in the non-treated group, the average weight of the pancreas decreased with aging (Table 3) , indicating a gradual pancreatic atrophy.
Meanwhile, among 8 rats in the camostatmesylate-treated group during the progression stage, 7 rats exhibited a lower than 25% pancreatitic area, indicating that the drug was very effective as the histological photo shows in Fig. 3 -a. And 1 rat had a 26-50% pancreatitic area, indicating that the drug was effective. These results indicate that camostat mesylate was 100% effective in all rats ( Table   4 ). The rat pancreatic tissue to which camostat mesylate was administered clearly exhibited hypertrophy of acinar cells (Fig. 3-d ) compared to the non-treated group (Fig. 3-f) . The weight of the pancreas in this group increased even with the administration of the drug during the progression stage and became approximately 2.7-fold higher than that in the non-treated group. No significant differences in the serum enzyme, PFD or IRI levels were observed between the initial and progression stages in the non-treated group (Table 3) .
Among 5 rats in the allopurinol-treated group during the progression stage, one rat exhibited a 26-50% pancreatitic area indicating that the drug is effective ; however 4 rats exhibited a (Table 4) . Histopathologically, the pancreatic acinus had a normal shape in part however, pancreatitic lesions were observed in many places (Fig. 3-b) . Hypertrophy of acinar cells was not observed in the allopurinoltreated group (Fig. 3-e) , resulting in no significant increase in the weight of the pancreas compared to that of the non-treated group (Table 3) . No significant differences in the levels of PFD, pancreatic enzyme series or IRI were observed between the treated and nontreated groups (Table 3) .
3) Study of pancreatic regeneration (Fig. 4-a) . These observations indicated the regeneration and proliferation of acinar cells in the damaged region. On the other hand, after peroral administration of camostat mesylate, which is a trypsin inhibitor, for 8 weeks in rats from 18 weeks old, BrdU uptake into regenerated and proliferated acinar cells was not observed (Fig. 4-b Recently, involvement of activated oxygen in inflammation has been suspected. There is a report describing that a drug that removes activated oxygen is effective at preventing the development of experimentally induced acute pancreatitis12). In this study, to remove activated oxygen, SOD at a dose of 50 mg/kg body weight and catalase at a dose of 10 mg/kg body weight were subcutaneously administered twice a week, but they were unable to prevent the development of pancreatitis in WBN rats.
Before combining SOD and catalase, the concentrations at which they were administered were determined based on a previous report12) Pancreatic biopsy in the actual clinical field is almost impossible, therefore how chronic pancreatitis progresses and the effectivity of the drugs with time cannot be studied. Under such circumstances, it is concluded that the WBN rat is a good chronic pancreatitis model that is highly effective not only for studying the progression of the disease from chronic pancreatitis, but also for pharmacological studies of drugs for chronic pancreatitis.
Conclusion
(1) A new evaluation method for the treatment of chronic pancreatitis using the WBN/ Kob rat as a human chronic pancreatitis model was determined.
(2) As a result of screening for drugs that inhibit the development of pancreatic lesions in WBN rats, the inhibitory effects of estradiol, camostat mesylate and allopurinol were observed. (6) The most effective parameter for evaluating the efficacy of a drug for pancreatitis is the percentage of pancreatitic area employed in our histopathological study. It was possible to evaluate drugs for chronic pancreatitis treatment using this parameter.
Accordingly, we concluded that the use of WBN/Kob rats is effective for drug evaluation in the treatment of chronic pancreatitis.
